OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-1.03%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$438M
AUM Growth
+$438M
(-4.6%)
Cap. Flow
+$11.6M
Cap. Flow
% of AUM
2.65%
Top 10 Holdings %
Top 10 Hldgs %
58.99%
Holding
62
New
9
Increased
15
Reduced
17
Closed
11
Top Buys
| 1 |
Immunome
IMNM
|
$13.3M |
| 2 |
Cytokinetics
CYTK
|
$10.8M |
| 3 |
CRGX
CARGO Therapeutics
CRGX
|
$9.12M |
| 4 |
Arvinas
ARVN
|
$5.99M |
| 5 |
Biodesix
BDSX
|
$5.33M |
Top Sells
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$9.83M |
| 2 |
Ocular Therapeutix
OCUL
|
$9.2M |
| 3 |
Compass Therapeutics
CMPX
|
$6.28M |
| 4 |
Catalyst Pharmaceutical
CPRX
|
$5.64M |
| 5 |
NYXH
Nyxoah
NYXH
|
$4.32M |
Sector Composition
| 1 | Healthcare | 98.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Context Therapeutics
CNTX
$75.6M
| – | – |
-1,108,357
| Closed | -$1.53M |
|
|
52
Crinetics Pharmaceuticals
CRNX
$3.26B
| – | – |
-210,000
| Closed | -$9.83M |
|
53
Glaukos
GKOS
$5.42B
| – | – |
-8,576
| Closed | -$809K |
|
54
Larimar Therapeutics
LRMR
$337M
| – | – |
-174,413
| Closed | -$1.32M |
|
|
NYXH
55
Nyxoah
NYXH
$221M
| – | – |
-320,000
| Closed | -$4.32M |
|
56
Precigen
PGEN
$1.42B
| – | – |
-947,500
| Closed | -$1.37M |
|
57
Repare Therapeutics
RPTX
$73.9M
| – | – |
-67,561
| Closed | -$318K |
|
58
Zentalis Pharmaceuticals
ZNTL
$123M
| – | – |
-200,000
| Closed | -$3.15M |
|
|
RVNC
59
DELISTED
Revance Therapeutics, Inc.
RVNC
| – | – |
-785,000
| Closed | -$3.86M |
|
|
MOR
60
DELISTED
MorphoSys AG American Depositary Shares
MOR
| – | – |
-65,000
| Closed | -$1.18M |
|